北京市癌症疼痛管理规范(2017年版)

2017-12-30 北京市疼痛治疗质量控制和改进中心癌痛专家组 中国疼痛医学杂志.2017,23(12):881-889.

为进一步规范我国癌痛诊疗行为,完善重大疾病规范化诊疗体系,提高医疗机构癌痛诊疗水平,改善癌症病人生活质量,保障医疗质量和医疗安全,原卫生部制定并发布了《癌症疼痛诊疗规范》(2011年版)。自该文件发布以后,在国家各级卫生行政部门的领导下,通过医护人员的努力,癌痛诊疗水平有了较大的提高。为了更好地适应这种现状,进一步规范北京市癌痛诊疗行为,在参照原卫生部发布的《癌症疼痛诊疗规范》(2011 年版)及

中文标题:

北京市癌症疼痛管理规范(2017年版)

发布日期:

2017-12-30

简要介绍:

为进一步规范我国癌痛诊疗行为,完善重大疾病规范化诊疗体系,提高医疗机构癌痛诊疗水平,改善癌症病人生活质量,保障医疗质量和医疗安全,原卫生部制定并发布了《癌症疼痛诊疗规范》(2011年版)。自该文件发布以后,在国家各级卫生行政部门的领导下,通过医护人员的努力,癌痛诊疗水平有了较大的提高。为了更好地适应这种现状,进一步规范北京市癌痛诊疗行为,在参照原卫生部发布的《癌症疼痛诊疗规范》(2011 年版)及《北京市癌症疼痛诊疗质控专家共识》(2014 年版)的基础上,结合北京市67 家医院癌痛督导中的问题而制订《北京市癌症疼痛管理规范》(2017 年版)。

 

拓展指南:疼痛相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=北京市癌症疼痛管理规范(2017年版))] GetToolGuiderByIdResponse(projectId=1, id=ea47c1c0015395b6, title=北京市癌症疼痛管理规范(2017年版), enTitle=, guiderFrom=中国疼痛医学杂志.2017,23(12):881-889., authorId=null, author=, summary=为进一步规范我国癌痛诊疗行为,完善重大疾病规范化诊疗体系,提高医疗机构癌痛诊疗水平,改善癌症病人生活质量,保障医疗质量和医疗安全,原卫生部制定并发布了《癌症疼痛诊疗规范》(2011年版)。自该文件发布以后,在国家各级卫生行政部门的领导下,通过医护人员的努力,癌痛诊疗水平有了较大的提高。为了更好地适应这种现状,进一步规范北京市癌痛诊疗行为,在参照原卫生部发布的《癌症疼痛诊疗规范》(2011 年版)及, cover=, journalId=null, articlesId=null, associationId=1573, associationName=北京市疼痛治疗质量控制和改进中心癌痛专家组, associationIntro=, copyright=0, guiderPublishedTime=Sat Dec 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>为进一步规范我国癌痛诊疗行为,完善重大疾病规范化诊疗体系,提高医疗机构癌痛诊疗水平,改善癌症病人生活质量,保障医疗质量和医疗安全,原卫生部制定并发布了《癌症疼痛诊疗规范》(2011年版)。自该文件发布以后,在国家各级卫生行政部门的领导下,通过医护人员的努力,癌痛诊疗水平有了较大的提高。为了更好地适应这种现状,进一步规范北京市癌痛诊疗行为,在参照原卫生部发布的《癌症疼痛诊疗规范》(2011 年版)及《北京市癌症疼痛诊疗质控专家共识》(2014 年版)的基础上,结合北京市67 家医院癌痛督导中的问题而制订《北京市癌症疼痛管理规范》(2017 年版)。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>疼痛</FONT>相关指南:</STRONG><BR> <UL> <LI><A title="2017 ASRA/ESRA/AAPM/INS/NANS/WIP指南:服用抗血小板和抗凝药物患者进行脊柱和疼痛介入治疗(第2版)" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=12c2e1c00153e8c3">2017 ASRA/ESRA/AAPM/INS/NANS/WIP指南:服用抗血小板和抗凝药物患者进行脊柱和疼痛介入治疗(第2版)</A> <LI><A title="2017 ASPMN/HPNA立场声明:临终期疼痛的管理" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=aa5f21c001536145">2017 ASPMN/HPNA立场声明:临终期疼痛的管理</A> <LI><A title="2017 亚太专家组共识建议:应用外用非甾体类抗炎药管理骨关节炎疼痛" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=2ec341c00153a54c">2017 亚太专家组共识建议:应用外用非甾体类抗炎药管理骨关节炎疼痛</A> <LI><A title="2017 共识建议:接受阿片类药物治疗的慢性疼痛患者合理的尿液药物监测" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=9259e1c00153039e">2017 共识建议:接受阿片类药物治疗的慢性疼痛患者合理的尿液药物监测</A> <LI><A title="2017 IDSA临床实践指南:HIV感染患者慢性疼痛的管理" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=962b01c0015085aa">2017 IDSA临床实践指南:HIV感染患者慢性疼痛的管理</A> 更多信息请点击:<A target=_blank href="http://www.medsci.cn/guideline/list.do?q=%E7%96%BC%E7%97%9B">有关疼痛更多指南</A></LI></UL>, tagList=[TagDto(tagId=31157, tagName=癌症疼痛)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6278, appHits=239, showAppHits=0, pcHits=4933, showPcHits=1796, likes=130, shares=8, comments=3, approvalStatus=1, publishedTime=Fri Jan 05 00:34:32 CST 2018, publishedTimeString=2017-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Jan 05 00:34:32 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:27:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=北京市癌症疼痛管理规范(2017年版))])
北京市癌症疼痛管理规范(2017年版)
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=277628, encodeId=03822e7628f9, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzz90aiaSfF40JFA1hmhplehvSoTTxlp8MkbNTwYic113UtH7lwmvIq4aRreYj4olIF3Bf6mQic6RrA/132, createdBy=6ab82245439, createdName=否定精灵, createdTime=Thu Jan 11 22:20:35 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275618, encodeId=a1e52e5618b7, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 05 08:00:38 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275545, encodeId=f0ff2e554552, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Fri Jan 05 02:12:38 CST 2018, time=2018-01-05, status=1, ipAttribution=)]
    2018-01-11 否定精灵

    规范

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=277628, encodeId=03822e7628f9, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzz90aiaSfF40JFA1hmhplehvSoTTxlp8MkbNTwYic113UtH7lwmvIq4aRreYj4olIF3Bf6mQic6RrA/132, createdBy=6ab82245439, createdName=否定精灵, createdTime=Thu Jan 11 22:20:35 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275618, encodeId=a1e52e5618b7, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 05 08:00:38 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275545, encodeId=f0ff2e554552, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Fri Jan 05 02:12:38 CST 2018, time=2018-01-05, status=1, ipAttribution=)]
    2018-01-05 Y—xianghai

    学习了新知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=277628, encodeId=03822e7628f9, content=规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJzz90aiaSfF40JFA1hmhplehvSoTTxlp8MkbNTwYic113UtH7lwmvIq4aRreYj4olIF3Bf6mQic6RrA/132, createdBy=6ab82245439, createdName=否定精灵, createdTime=Thu Jan 11 22:20:35 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275618, encodeId=a1e52e5618b7, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Jan 05 08:00:38 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275545, encodeId=f0ff2e554552, content=学习学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Fri Jan 05 02:12:38 CST 2018, time=2018-01-05, status=1, ipAttribution=)]
    2018-01-05 jihuaijun1112

    学习学习学习

    0